This month we are honored to feature an article written by one of our Steffens medical advisers, Dr Whelan. It summarizes the current areas of Degos research for this ultra-rare disease. This is followed by summaries of two local Scleroderma projects currently underway
Scleroderma is a rare disease that leads to fibrosis or hardening of the skin and connective tissue. The disease varies from person to person in terms of extent, its patterns of skin and organ involvement, and the rate of progression. It can also affect the lungs, kidneys, heart and other internal organs. In the U.S., approximately 100,000 people have scleroderma.
Atrophic papulosis or Degos disease (DD) has 2 variants: 1) a more common, limited, cutaneous type, which can be referred to as benign atrophic papulosis (BAP) and 2) a severe systemic
